Core Insights - The pharmaceutical industry is witnessing significant strategic collaborations, with companies like Kangzheng Pharmaceutical partnering with global giants like Novartis to enhance their market presence in specialized fields such as ophthalmology and dermatology [1] Group 1: Kangzheng Pharmaceutical's Strategic Moves - Kangzheng Pharmaceutical has signed a distribution agreement with Novartis, gaining exclusive rights for two ophthalmic drugs in mainland China, indicating a strong commitment to the ophthalmology sector [1] - The company is also focusing on its dermatology segment through the spin-off of its skin health business, Dermy Pharmaceuticals, which has submitted a listing application to the Hong Kong Stock Exchange [1] Group 2: Market Potential in Dermatology - The white spot disease (vitiligo) market is highlighted as a significant opportunity, with the treatment market projected to grow from 2.8 billion RMB in 2024 to approximately 21.9 billion RMB by 2035, reflecting a compound annual growth rate (CAGR) of 20.7% [2] - Dermy Pharmaceuticals is advancing its lead product, Ruxolitinib cream, which is the first and only FDA and EMA-approved topical JAK inhibitor for vitiligo, currently in the new drug application approval stage in China [3] Group 3: Other Dermatological Conditions - Psoriasis, affecting around 7.2 million patients in China, is seeing a shift towards biologics and small molecule drugs as preferred treatment options, with Dermy Pharmaceuticals' Tildrakizumab injection positioned as a second approved IL-23 monoclonal antibody in the market [4] - Atopic dermatitis, impacting over 54 million people in China, is expected to see its treatment market grow from 12.1 billion RMB in 2024 to 39.4 billion RMB by 2035, with Dermy Pharmaceuticals pursuing multiple pipeline strategies to address this demand [6][7] Group 4: Acne Treatment Innovations - Acne is a prevalent skin issue, with a reported prevalence of 8.1% in the Chinese population, leading to a growing market for effective skincare solutions [8] - Dermy Pharmaceuticals is leveraging its brand advantage with the launch of the Xiliao Duo series, targeting acne treatment and prevention, while also offering soothing products for atopic dermatitis and sensitive skin [8]

Core Insights - The theme for World Psoriasis Day 2025 is "Stop the Domino Effect," emphasizing the need for global awareness of psoriasis as a systemic immune disease and the importance of early intervention, comprehensive care, and equitable access to medical resources [1] Group 1: Disease Overview - Psoriasis is a chronic, recurrent, inflammatory, and systemic disease triggered by genetic and environmental factors, and it is non-contagious [1] - In China, there are nearly 7 million psoriasis patients, with about two-thirds developing the condition before the age of 40, impacting their education and employment [1] Group 2: Patient Challenges - Psoriasis patients often face significant mental stress and fear of disclosing their condition in academic and workplace settings, which can alter their career trajectories [1] Group 3: Treatment Insights - Long-term and stable disease control is crucial for psoriasis patients to return to normal learning and work environments [2] - Although psoriasis cannot be cured, international studies indicate that early use of appropriate biological agents can lead to up to 2.5 years of skin lesion remission with a standardized one-year treatment and long-term management [2] Group 4: Company Initiatives - Johnson & Johnson has launched an upgraded public welfare project and a survey on career development insights for psoriasis patients, supported by Minsheng Weekly [2] - The company emphasizes a patient-first approach, focusing on innovative treatment solutions and digital tools for comprehensive patient support throughout the treatment cycle [2]

Core Viewpoint - The study identifies CCR7+ dendritic cells as the primary source of IL-23 in psoriasis, providing a cellular framework for developing therapies aimed at achieving long-term relief from psoriasis and related chronic inflammation [3][4][7]. Group 1: Research Findings - The research reveals that IL4I1+ CD200+ CCR7+ dendritic cells (CCR7+ DC) express both IL-23A and IL-12B, making them the main producers of IL-23 in psoriasis [4][7]. - CCR7+ DC can drive psoriasis relapse through a spatially organized "Th17 module," recruiting IL-17 producing CD161+ T cells and activating keratinocytes responsive to IL-17 [7][8]. - The absence of CCR7+ DC in mouse models completely inhibits IL-23 production, while forced expression of IL-23A in these cells induces psoriasis-like skin disease and arthritis [8]. Group 2: Implications for Therapy - The findings provide a cellular basis for developing therapies that can disrupt the persistent presence of IL-23, potentially leading to sustained relief from psoriasis and associated chronic inflammation [4][8].

关于全资子公司获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：000963 证券简称：华东医药 公告编号：2025-013 华东医药股份有限公司 上市许可持有人：杭州中美华东制药有限公司 生产企业：江苏赛孚士生物技术有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品此次申请事项符合药品注册的有关要求，批准本品增加 "儿童斑块状银屑病。本品适用于对其他系统性治疗或光疗应答不足 或无法耐受的6岁及以上儿童和青少年（体重60公斤至100公斤）中重 度斑块状银屑病患者。"的补充申请，并修订说明书有关内容，说明 书按附件执行。 二、该药物研发及注册情况 HDM3001（QX001S）是原研产品Stelara®（喜达诺®，乌司奴单 抗注射液）的生物类似药，作用机理为阻断IL-12和IL-23共有的p40 亚基与靶细胞表面的IL-12Rβ1受体蛋白的结合，从而抑制IL-12和IL- 23介导的信号传导和细胞因子级联反应。IL-12和IL-23是两种天然存 在的细胞因子，在免疫介导的炎症性疾病中发挥着关键 ...